Search results
Emerging Life Sciences Companies Deskbook: Author: Morgan, Lewis & Bockius: Edition: 2: Publisher: Morgan, Lewis & Bockius, 2008 : Export Citation: BiBTeX EndNote RefMan
This document discusses important areas of due diligence for companies considering partnering or acquiring another company's pharmaceutical or biologic products. It outlines key areas to examine including intellectual property, regulatory status of products, marketing applications, drug master files, preclinical and clinical research conducted, ...
12 Emerging Life Sciences Companies Deskbook The following is a detailed outline of various issues to consider when spinning out a new venture. Reasons for Spinning Out A. To free the Company from its parent’s resource allocation and planning decisions and other constraints that may not be consistent with its health and growth
16 Emerging Life Sciences Companies Deskbook Chapter 3 CORPORATE gOVERnAnCE ISSuES Corporate governance is a combination of (i) principles, (ii) policies, and (iii) procedures designed to enable the board of directors to manage the Company in accordance with duties owed to stockholders and other Company stakeholders.
50 Emerging Life Sciences Companies Deskbook Chapter 7 FREEDOM TO OPERATE As life sciences companies develop their patent portfolios, they come to realize that being able to patent their inventions is only the beginning. They must also be able to use their inventions to make and sell products.
Emerging life sciences companies deskbook: 1. Emerging life sciences companies deskbook. by Morgan, Lewis & Bockius. Print book: English. 2008. 2nd ed [Philadelphia?] : Morgan, Lewis & Bockius 2. Emerging life sciences companies deskbook: 2. Emerging life sciences companies deskbook. by Morgan, Lewis & Bockius. Print book:
new trends emerging that will shape the future of this rapidly changing industry. The global stage has witnessed significant upheavals throughout 2023, with wars impacting everything from oil prices to work locations. Inflation and rising material costs cutting into the profits of many life science companies, and a continuation of the COVID
